Lytix Biopharma AS, a clinical stage immuno-oncology company, announces the election of a new Chairman of the Board at ‘s General Assembly.
Lytix Biopharma appoints new Chairman of the Board Read More »
Nona Biosciences announced it has entered into a collaboration agreement with Michael S. Diamond, MD, PhD, of Washington University in St. Louis to discover viral targets for which few or no human monoclonal antibodies currently exist, such as western equine encephalitis virus, rabies and severe fever with thrombocytopenia syndrome virus.
Nona Biosciences and Washington University Join Forces to Tackle Emerging RNA Viruses Read More »
ImmVira presented preclinical study results of CAR-T enabler oHSV product MVR-7011 through poster publication at the American Association for Cancer Research annual meeting.
Modalis Therapeutics Corporation announced that the abstract has been accepted for a presentation in the late-breaking session at the 26th Annual Meeting of The American Society of Gene & Cell Therapy, being held in Los Angeles CA on May 16-20, 2023.
Gamida Cell Ltd. announced the launch of a follow-on public offering of its ordinary shares and accompanying warrants to purchase its ordinary shares.
Gamida Cell Announces Launch of Public Offering of Securities – April 19, 2023 Read More »
Biophytis SA announced that it has received written notification from the Nasdaq Stock Market LLC dated April 14, 2022, indicating that Biophytis has regained compliance with he Nasdaq Global Select Market minimum bid price requirement.
Biophytis Regains Compliance with NASDAQ Minimum Bid Price Requirement Read More »
Everest Medicines announced that it has signed a Memorandum of Understanding for a strategic partnership with a subsidiary of Shanghai Pharma, SPH Keyuan Xinhua Pharmaceutical Co., Ltd.
Agilis Robotics, an innovative spin-off company from The University of Hong Kong, is making waves in the realm of endoscopic surgery with its flexible robotic arms.
Cali Biosciences Co., Ltd. announced it has initiated Phase III studies of its core product, CPL-01, with dosing in hernia patients already begun and dosing in bunion patients scheduled to start next month.
Enamine Ltd., a provider of drug discovery services empowered with the world’s largest collections of building blocks, fragments, and screening compounds, gave an update of its long-standing research collaboration with Endogena Therapeutics AG, a clinical-stage biotech company focused on the development of endogenous regenerative medicines.
